definiens: shall mean rights under the following patents and patent applications : [ US 5,429,746, PCTIUS95/01823, US RE40,070, EP 746398, GB 9022011, PCT / GB91/01744, US 5,858,725, EP 552266, JP 3516950, UK 9115284.3, UK 9116594.4, UK 9206284.3, PCT / GB92 /01282, US 5,876,961, US 901006,997, US 111289,714, EP 523949, GB 9022545, US 5,316,938, US 5,633,162, US RE39,792, US 111640,428, EP 481791, EP 1221476, EP 1849862, GB 9022543, US 5,545,403, US 5,545,404, US 5,545,405, US 101145,992, US 10/765,067, US 12/122,123, EP 481790, and EP 1247865, ] and any and all patents that are issued therefrom, together with any and all substitutions, continuations, divisionals, continuations - in - part, reissues, renewals, registrations, confirmations, reexaminations, extensions including EAST\44148436.1 Execution Version supplementary protection certificates, foreign equivalents or counterparts, and other filings thereof . [COMPANY] Additional Patent Rights shall also include rights under any patents or patent applications ( other than [COMPANY] Arising Patents ) which are owned or Controlled by [COMPANY] or any of its Affiliates during the Term that claim the Development and/or Commercialization of belimumab or Collaboration Product